| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/15/2007 | WO2006135480A9 Oral pharmaceutical formulations comprising fenofibric acid and/or its salts |
| 02/15/2007 | WO2006133242A3 Azinone and diazinone v3 inhibitors for depression and stress disorders |
| 02/15/2007 | WO2006131392A8 Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| 02/15/2007 | WO2006130297A3 Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene |
| 02/15/2007 | WO2006124770A3 Treatment of sepsis and inflammation with alpha2a adrenergic antagonists |
| 02/15/2007 | WO2006123354A3 Oral pharmaceutical composition |
| 02/15/2007 | WO2006122925A3 Oral medicament based on a proton pump inhibitors |
| 02/15/2007 | WO2006120035A3 Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate |
| 02/15/2007 | WO2006116656A3 Compositions comprising triterpene saponins and compounds with functional angeloyl groups for inhibition of venous insufficiency, leg swelling and tumors |
| 02/15/2007 | WO2006115547A8 Dendritic polymers with enhanced amplification and interior functionality |
| 02/15/2007 | WO2006113731A9 Bone marrow-derived neurogenic cells and uses thereof |
| 02/15/2007 | WO2006113606A3 Histone deacetylase inhibitors |
| 02/15/2007 | WO2006111285A3 Imino-oxazolidines and use thereof as anticoagulants |
| 02/15/2007 | WO2006108599A3 Ghrelin binding nucleic acids |
| 02/15/2007 | WO2006106521A8 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
| 02/15/2007 | WO2006105838A3 Use of a combination of vitamins b and phytosterols for lowering blood pressure |
| 02/15/2007 | WO2006103638A3 Topical pharmaceutical compositions of terbinafine and processes for their preparation |
| 02/15/2007 | WO2006103120A3 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
| 02/15/2007 | WO2006103119A3 Tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics |
| 02/15/2007 | WO2006101920A3 Compositions and methods related to the manipulation of adenosine 2a receptor signaling for the treatment of hiv associated neuronal damage |
| 02/15/2007 | WO2006100087A3 Solid oral dosage form of valopi citabine (val-mcyd) and method of preparing it |
| 02/15/2007 | WO2006094811A3 Use of microtubule stabilizing compounds for the treatment of lesions of cns axons |
| 02/15/2007 | WO2006094737A3 Gastroresistant pharmaceutical formulations containing rifaximin |
| 02/15/2007 | WO2006085013A3 Use of silymarine and/or the constituents thereof as promoters of the pigmentation of the skin or hair |
| 02/15/2007 | WO2006081337A3 Erastin analogues and their uses for killing cancer cells |
| 02/15/2007 | WO2006078752A3 Inhibitors of dna methyltransferase |
| 02/15/2007 | WO2006076734A3 Prodrugs of short-chain fatty acids and treatment methods |
| 02/15/2007 | WO2006076644A3 Heteroaryl sulfonamides and ccr2 |
| 02/15/2007 | WO2006067614B1 Heteroaromatic derivatives useful as anticancer agents |
| 02/15/2007 | WO2006062424A3 Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system |
| 02/15/2007 | WO2006055472A3 Synthetic discodermolide analogs |
| 02/15/2007 | WO2006050302A3 Dye-free pharmaceutical suspensions and related methods |
| 02/15/2007 | WO2006026713A3 Topical benfotiamine and pyridoxamine compositions |
| 02/15/2007 | WO2006023702A3 Method for treating sleep related breathing disorders with setiptiline |
| 02/15/2007 | WO2006020060A3 Iap binding compounds |
| 02/15/2007 | WO2006016912A3 Synthesis of (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates and composition and uses thereof |
| 02/15/2007 | WO2006009975A3 Histamine to treat disorders affecting muscle function |
| 02/15/2007 | WO2005123703A8 Alkynyl derivatives as modulators of metabotropic glutamate receptors |
| 02/15/2007 | WO2005121378A3 Methods and compositions for vaccination |
| 02/15/2007 | WO2005107810A3 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| 02/15/2007 | WO2005099715A9 Treatment of ophthalmic conditions with mineralcorticoids |
| 02/15/2007 | WO2005089472A3 Anti-adhesion spraying |
| 02/15/2007 | US20070039064 Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| 02/15/2007 | US20070039063 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy |
| 02/15/2007 | US20070037984 Biphenyl derivatives |
| 02/15/2007 | US20070037979 Preparation of rosuvastatin |
| 02/15/2007 | US20070037890 Cannabinoids |
| 02/15/2007 | US20070037889 Anticancer composition comprising obovatol or obovatal |
| 02/15/2007 | US20070037888 4-(Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| 02/15/2007 | US20070037887 Blockade of mtor to prevent a hormonal adaptive response |
| 02/15/2007 | US20070037886 Bone marrow erythroid progenitor cell(s) differentiation inducer |
| 02/15/2007 | US20070037885 Biomass containing animal feed |
| 02/15/2007 | US20070037884 Novel succinate salt of O-desmethyl-venlafaxine |
| 02/15/2007 | US20070037883 Therapeutic compositions |
| 02/15/2007 | US20070037882 Remedy for cerebral neurodegenerative diseases using ppar agonist |
| 02/15/2007 | US20070037881 Amidoacetonitrile derivatives |
| 02/15/2007 | US20070037880 administering a topical formulation containing ascorbic acid to a patient for treating vaginal infection; formulation is vaginally administered after completion of a standard treatment against bacterial, fungal or protozoarian infections; sustained release |
| 02/15/2007 | US20070037879 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/15/2007 | US20070037878 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 02/15/2007 | US20070037877 trifluoro-methanesulfonic acid 3-(2,4-dimethoxy-phenyl)-4-(2-methoxy-ethyl)-2-oxo-2H-chromen-7-yl ester as potassium channel modulators; urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowl syndrome, airway hyperactivity |
| 02/15/2007 | US20070037875 Genistein inhibition of transthyretin amyloidosis |
| 02/15/2007 | US20070037874 Manufacturing process of isoflavan or isoflavene derivatives |
| 02/15/2007 | US20070037873 Airway remodeling treatments |
| 02/15/2007 | US20070037872 Inducing peripheral blood vesel vasodilation |
| 02/15/2007 | US20070037871 Pkc activation as a means for enhancing sappalpha secretion and improving cognition using bryostatin type compounds |
| 02/15/2007 | US20070037870 Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
| 02/15/2007 | US20070037869 Histone deacetylase inhibitors |
| 02/15/2007 | US20070037868 Macrocyclic diaminopropanes as beta-secretase inhibitors |
| 02/15/2007 | US20070037867 Antihepatitis c virus agent and anti-hiv agent |
| 02/15/2007 | US20070037866 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt |
| 02/15/2007 | US20070037865 Sirtuin modulating compounds |
| 02/15/2007 | US20070037864 Intermediates for the preparation of lipoxin A4 analogs |
| 02/15/2007 | US20070037863 Dipeptide phenyl ethers |
| 02/15/2007 | US20070037862 inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases |
| 02/15/2007 | US20070037861 Enhanced method of treatment of growth disorders |
| 02/15/2007 | US20070037860 Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy |
| 02/15/2007 | US20070037859 Substituted Thiazolidinedione Derivative, Process for Its Preparation and Its Pharmaceutical Use |
| 02/15/2007 | US20070037857 Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| 02/15/2007 | US20070037856 Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease |
| 02/15/2007 | US20070037855 Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
| 02/15/2007 | US20070037854 Process for preparing sulfonamide-containing indole compounds |
| 02/15/2007 | US20070037853 N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition |
| 02/15/2007 | US20070037852 Migrastatin analogs and uses thereof |
| 02/15/2007 | US20070037851 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells |
| 02/15/2007 | US20070037850 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| 02/15/2007 | US20070037849 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea; angiogenesis neoplasia |
| 02/15/2007 | US20070037848 Treatment of neurological conditions |
| 02/15/2007 | US20070037847 Intrathecal administering of LY293558 or 6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinolone-3-carboxylic acid; side effect reduction |
| 02/15/2007 | US20070037846 Pyrazolidinedione derivatives |
| 02/15/2007 | US20070037845 Peptido-mimetic compounds containing rgd sequence useful as integrin inhibitors, and intermediates thereof |
| 02/15/2007 | US20070037844 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia |
| 02/15/2007 | US20070037843 Zolpidem hemitartrate |
| 02/15/2007 | US20070037842 Polymorphs and amorphous form of (s)-(+)-clopidogrel bisulfate |
| 02/15/2007 | US20070037841 Inhibitors |
| 02/15/2007 | US20070037840 Tricyclic benzimidazoles |
| 02/15/2007 | US20070037839 useful in Pharmaceutical medicines or pharmacological tools; cytostatic agents; antiproliferative/antineoplastic agents; 2-Anilino-4-[1-isopropyl-2-(hydroxyiminomethyl)imidazol-5-yl]pyrimidine; rheumatoid arthritis; breast cancer |
| 02/15/2007 | US20070037838 Substance which exhibits antiviral and antibacterial activity and is based on derivatives of 2,8-dithioxo-1h-pyrano[2,3d 6,5-d']dipyrimidyne and 10-aza-analogue thereof |
| 02/15/2007 | US20070037837 Quinazoline derivatives |
| 02/15/2007 | US20070037836 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide |
| 02/15/2007 | US20070037835 Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid |